Featured news from NHIVNA
HIV-related news from NAM
Abbott interferon-free HCV combinations show early promise in untreated patients
Keith Alcorn, 2012-04-23 17:10:00
Two interferon-free antiviral regimens being developed by Abbott showed high hepatitis C cure rates in small studies of treatment-naïve patients presented last week at the International Liver Congress in Barcelona.
Abbott is pursuing the development of several interferon-free regimens in which the investigational protease inhibitor ABT-450, boosted with the CYP3A inhibitor ritonavir in order to allow once-daily dosing, is combined with a non-nucleoside polymerase inhibitor.
The first study to be presented combined ABT-450 with the non-nucleoside HCV NS5B inhibitor ABT-072, also dosed once daily, both dosed with ribavirin.
The combination was evaluated in eleven treatment-naïve patients with HCV genotype 1. None had cirrhosis and all had the IL28B CC genotype in order to maximize the possibility of successful second-line treatment with pegylated interferon and ribivirin in the event of treatment failure.
They received treatment lasting twelve weeks. This consisted of the investigational protease inhibitor ABT-450, at a dose of 150 mg once daily with a 100mg ritonavir booster. This was combined with 400 mg once-daily dose of ABT-072 and weight-based ribavirin (1000 – 1200mg), dosed twice daily. The aim of the study was to assess the safety, tolerability, pharmacokinetics and antiviral activity of the two investigational drugs.
Viral load was monitored throughout
treatment, on its completion at week twelve and again 24 weeks after therapy
was finished. An undetectable viral load ( Approximately three-quarters of patients
(73%) were men and 82% were white. Median
baseline viral load was 6.9 log10 iu/ml and in all patients
was above 800,000 copies iu/ml. The investigational regimen was shown to
have a rapid and sustained anti-hepatitis C effect. All the patients had a viral load below 25
iu/ml by week three and this remained suppressed until the end of therapy at
week twelve. Viral load rebounded in one patient eight
weeks after the completion of treatment, but in the others it remained
suppressed below the lower limit of quantification at week 24 (SVR24). A second
patient experienced viral breakthrough by 36 weeks post-treatment, leading to a
SVR 36 of 81%. There were no deaths or serious
side-effects. The most commonly reported adverse events, all of which were
mild, included headache (36%), fatigue (27%), nausea (27%) and dry skin (27%).
Two patients developed indirect bilirubin elevations (2xULN) within the first
week of treatment, but these resolved with further dosing and were not
associated with transaminase elevations. ABT-450/r
and ABT-333 The second study to be presented was the
combination of ABT-450/ritonavir and the twice-daily non-nucleoside NS5B
polymerase inhibitor ABT-333, again combined with weight-based ribavirin. This regimen was evaluated both in
treatment-naïve patients with HCV genotype 1 and in previous non-responders to
pegylated interferon and ribavirin. IL28B CC genotype was not a requirement for
entry to this study, and patients in this trial were infected with HCV of the IL28B CT or TT
genotype associated with poorer response to interferon-based therapy. The study compared two doses of ABT-450/r
(250mg or 150mg, each boosted with 100mg of ritonavir) in treatment-naïve
patients. All prior non-responders received a dose of 150mg. All participants
received a 400mg dose of ABT-333. Treatment-naïve ABT-450/r
250mg + ABT-333 400mg N=19 Treatment-naïve ABT-450/r
150mg + ABT-333 400mg N=14 Previous
non-responders ABT-450/r
150mg + ABT-333 400mg N=17 RVR: HCV RNA
< 25 IU/ml at w4 90% 79% 88% eRVR: HCV RNA < 25 IU/ml weeks 4-12 90% 79% 65% Discontinuations 1, due to ALT/AST elevation 1 due to non-medical reason at w1 6 viral breakthroughs on treatment 3 viral relapse 2 weeks post-therapy SVR4: HCV RNA
< 25 IU/ml at w4 95% 93% 47% SVR12: HCV RNA
< 25 IU/ml at w12 95% 93% 47% No patients discontinued treatment due to
adverse events, but four patients experienced severe adverse events (fatigue,
pain, vomiting and hyperbilirubinaemia). The most common mild or moderate
adverse events were fatigue (42%), nausea and headache. Six patients
experienced elevations of indirect bilirubin, caused by ABT-450, which has an
effect on the bilirubin transporter OATP. Source:1